Advances in diagnosis and treatment of malignant pleural mesothelioma

被引：2
作者：
Scagliotti, Giorgio Vittorio [1 ,2 ]
Selvaggi, Giovanni [2 ]
机构：
[1] Univ Turin, Dept Clin & Biol Sci, Thorac Oncol Unit, San Luigi Hosp, Reg Gonzole 10, I-10043 Orbassano, TO, Italy
[2] Univ Turin, Dept Clin & Biol Sci, Thorac Oncol UNIT, San Luigi Hosp, Turin, Italy
来源：
ONCOLOGY REVIEWS | 2007年 / 1卷 / 02期
关键词：
Malignant Pleural Mesothelioma; Prognostic Factors; Mesothelin; Osteopontin; Chemotherapy; Pemetrexed; Targeted Therapy; Vascular Endothelial Growth Factor; Epidermal Growth Factor;
D O I：
10.1007/s12156-007-0011-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Malignant pleural mesothelioma (MPM) is an aggressive but relatively rare malignancy with median survival ranging from 8 to 14 months depending on stage and presentation of disease. New diagnostic procedures are urgently needed, selecting patients in earlier stages to evaluate therapeutic approaches which combine chemotherapy, surgery and radiotherapy. Combination chemotherapy represents the only resource available for advanced disease. The combination of cisplatin and pemetrexed is the treatment of choice. This review summarizes the latest developments in diagnostic techniques and the available therapeutic options for the management of MPM. Particular attention is given to the molecular basis of biologically targeted therapies to be used in the future.
引用
收藏
页码：91 / 102
页数：12
相关论文
共 106 条
[61]   Global gene expression profiling of pleural mesotheliomas:: Overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction [J].
López-Ríos, F ;
Chuai, S ;
Flores, R ;
Shimizu, S ;
Ohno, T ;
Wakahara, K ;
Illei, PB ;
Hussain, S ;
Krug, L ;
Zakowski, MF ;
Rusch, V ;
Olshen, AB ;
Ladanyi, M .
CANCER RESEARCH, 2006, 66 (06) :2970-2979
[62]   Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].
Lynch, TJ ;
Bell, DW ;
Sordella, R ;
Gurubhagavatula, S ;
Okimoto, RA ;
Brannigan, BW ;
Harris, PL ;
Haserlat, SM ;
Supko, JG ;
Haluska, FG ;
Louis, DN ;
Christiani, DC ;
Settleman, J ;
Haber, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139
[63]   Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops [J].
Masood, R ;
Kundra, A ;
Zhu, ST ;
Xia, GB ;
Scalia, P ;
Smith, DL ;
Gill, PS .
INTERNATIONAL JOURNAL OF CANCER, 2003, 104 (05) :603-610
[64]   Novel marker D240, combined with calretinin, CEA, and TTF-1 - An optimal set of immunodiagnostic markers for pleural mesothelioma [J].
Mimura, Takeshi ;
Ito, Akihiko ;
Sakuma, Toshiko ;
Ohbayashi, Chiho ;
Yoshimura, Masahiro ;
Tsubota, Noriaki ;
Okita, Yutaka ;
Okada, Morihito .
CANCER, 2007, 109 (05) :933-938
[65]   Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends [J].
Montanaro, F ;
Bray, F ;
Gennaro, V ;
Merler, E ;
Tyczynski, JE ;
Parkin, DM ;
ENCR Working Grp .
CANCER CAUSES & CONTROL, 2003, 14 (08) :791-803
[66]  
Muers M, 2007, J CLIN ONCOL, V25
[67]   Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT [J].
Nakano, J. ;
Huang, C. ;
Liu, D. ;
Masuya, D. ;
Nakashima, T. ;
Yokomise, H. ;
Ueno, M. ;
Wada, H. ;
Fukushima, M. .
BRITISH JOURNAL OF CANCER, 2006, 95 (05) :607-615
[68]   A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial [J].
O'Brien, MER ;
Watkins, D ;
Ryan, C ;
Priest, K ;
Corbishley, C ;
Norton, A ;
Ashley, S ;
Rowell, N ;
Sayer, R .
ANNALS OF ONCOLOGY, 2006, 17 (02) :270-275
[69]   Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies [J].
O'Connor, OA ;
Heaney, ML ;
Schwartz, L ;
Richardson, S ;
Willim, R ;
MacGregor-Cortelli, B ;
Curly, T ;
Moskowitz, C ;
Portlock, C ;
Horwitz, S ;
Zelenetz, AD ;
Frankel, S ;
Richon, V ;
Marks, P ;
Kelly, WK .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) :166-173
[70]   The Role of osteopontin in lung disease [J].
O'Regan, A .
CYTOKINE & GROWTH FACTOR REVIEWS, 2003, 14 (06) :479-488
234567891011